UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus

Launched by ZHEJIANG UNIVERSITY · Apr 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called UCAR T-cell therapy for patients with a condition known as systemic lupus erythematosus (SLE), particularly those who have not responded well to traditional therapies. The goal is to see if this treatment is safe and effective in helping patients whose lupus is difficult to manage. The trial is open to adults aged 18 and older who meet specific requirements, including having a confirmed diagnosis of SLE and showing signs of active disease despite receiving standard treatments.

Participants in the trial can expect to receive the UCAR T-cell therapy, which uses specially modified cells from their own immune system to target and fight the disease. Since this is an early-phase study, it is primarily focused on safety, so participants will be closely monitored throughout the process. The trial is not yet recruiting participants, but it will involve a small group of up to 18 individuals at one location. If you're interested in this study, it's important to discuss it with your healthcare provider to see if you meet the eligibility criteria and if it could be a suitable option for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years
• • 2. Meet the 2019 European League against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for systemic lupus erythematosus; The diagnosis of lupus nephritis was consistent with renal biopsy within 6 months prior to the study, and the histological diagnosis (ISN/RPS2018 LN classification) was active nephritis type III or IV with or without type V. Meet the definition of refractory recurrence: conventional treatment remains ineffective for more than 6 months, or disease activity reappears after remission. Conventional treatment is defined as the use of glucocorticoids, along with one or more of the following immunomodulatory drugs: cyclophosphamide, antimalarial drugs, azathioprine, Mycophenolate Mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics such as rituximab, Beliumab, and Telitacicept.
• • 3. SLEDAI-2000 ≥8；
• • 4. The NIH activity index (AI) of lupus nephritis was \>2, and the chronicity index (CI) was increased; Urinary protein: creatinine ratio (UPCR)\>1.0g/g, or 24-hour urinary protein \>0.5g, with or without active urinary sediment with red blood cell precipitation.
• • 5. Flow cytometry detected positive B cell CD19 or BCMA in the patient's peripheral blood.
• 6. Functional requirements for major organs are as follows:
• • 1. The bone marrow function needs to meet: a Neutrophil count ≥ 0.5× 10 \^ 9/L; b. Hemoglobin ≥60g/L: c. Platelets ≥ 20 × 10 \^ 9/L.
• • 2. Liver function: ALT ≤ 3 × UL; AST ≤ 3×ULN# Total bilirubin ≤ 2.0 ×ULN (excluding Gilbert syndrome, total bilirubin ≤ 3.0 × ULN).
• • 3. Renal function: creatinine clearance rate (CrCl) ≥ 30 ml/min(Cockcroft/Gault formula, excluding acute CrCl decline caused by the disease itself).
• • 7. ECOG：0-1；
• • 8. Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.
• • 9. Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.
• Exclusion Criteria:
• • 1. Subjects with a history of severe drug allergies or allergic tendencies.
• • 2. Presence or suspicion of uncontrolled or treatment-required fungal,bacterial, viral, or other infections.
• • 3. Subjects with central nervous system diseases caused by autoimmune diseases or non-autoimmune diseases (including epilepsy, psychosis, organic brain syndrome, cerebral vascular accidents, encephalitis, central nervous system vasculitis).
• • 4. Subjects with insufficient cardiac function
• • 5. Subjects with congenital immunoglobulin deficiencies
• • 6. History of malignancy within five years
• • 7. Subjects with end-stage renal failure
• • 8. Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer higher than the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV)
• • 9. Subjects with psychiatric disorders and severe cognitive impairments
• • 10. Subjects who had participated in other clinical trials within 3 months prior to enrollment
• • 11. Subjects who have used immunosuppressive agents or biologics with therapeutic effects on the disease within five half-life before enrollment
• • 12. Pregnant women or women planning to conceive
• • 13. Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.